Print this page    •   Back to Web version of article

Medical News
Merck's HIV Drug Isentress Fails Once-a-Day Study

December 1, 2010

Taking the HIV drug Isentress once a day is not as effective as the standard twice-daily regimen, reported drug manufacturer Merck & Co. Based on these initial results, Merck is suspending the Phase III trial of once-daily dosing.

Isentress is the only HIV drug that works by blocking integrase, an enzyme that allows HIV to insert its genetic material into human DNA. Taken twice a day, Isentress is used among both previously treated and treatment-naive HIV patients.

The trial enrolled 775 patients who were taking other HIV medications in addition to Isentress. One subset received 800 milligrams of Isentress once-daily, another group received the standard 400-milligram dose twice per day.

After 48 weeks, HIV was lowered to undetectable levels in 83.2 percent of patients on the once-daily regimen and 88.9 percent of patients on the twice-daily schedule.

Back to other news for December 2010

Excerpted from:
Reuters
11.29.2010; Ransdell Pierson




This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art59694.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.